Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC).
Mignotte H, Lasset C, Bonadona V, Lesur A, Luporsi E, Rodier JF, Cutuli B, Lasry S, Mauriac L, Granon C, Kerr C, Giard S, Hill C, de Lafontan B, de Gislain C, D'Anjou J, Fondrinier E, Lefeuvre C, Parache RM, Chauvin F. Mignotte H, et al. Among authors: de lafontan b, de gislain c. Int J Cancer. 1998 May 4;76(3):325-30. doi: 10.1002/(sici)1097-0215(19980504)76:3<325::aid-ijc7>3.0.co;2-x. Int J Cancer. 1998. PMID: 9579567
Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer.
Namer M, Soler-Michel P, Turpin F, Chinet-Charrot P, de Gislain C, Pouillart P, Delozier T, Luporsi E, Etienne PL, Schraub S, Eymard JC, Serin D, Ganem G, Calais G, Maillart P, Colin P, Trillet-Lenoir V, Prevost G, Tigaud D, Clavère P, Marti P, Romieu G, Wendling JL. Namer M, et al. Among authors: de gislain c. Eur J Cancer. 2001 Jun;37(9):1132-40. doi: 10.1016/s0959-8049(01)00093-4. Eur J Cancer. 2001. PMID: 11378344 Clinical Trial.
[Leukemia and pre-leukemic conditions occurring after treatment of breast cancer].
Cutuli B, Janvier M, de la Rochefordière A, Julien JP, Isambert N, Alzieu C, Kerbrat P, de Lafontan B, van Lemmens L, Curé H, Ganem G, Baume D, Le Mevel A, Lorthoraly A, de Gislain C, Marchal C, Chevelle C, Lauche H, Serin D. Cutuli B, et al. Among authors: de gislain c. Presse Med. 2000 Jan 29;29(3):135-8. Presse Med. 2000. PMID: 10686962 Clinical Trial. French.
[Node negative breast cancers: the good and the bad cases].
Hery M, Granon C, Delozier T, Degislain C, Horner-Vallet D, Maisse P, Naja A, Petit JC, Weber B. Hery M, et al. Pathol Biol (Paris). 1990 Oct;38(8):836-8. Pathol Biol (Paris). 1990. PMID: 2274378 French. No abstract available.
Polyadenylic-polyuridylic acid plus locoregional and pelvic radiotherapy versus chemotherapy with CMF as adjuvants in operable breast cancer. A 6 1/2 year follow-up analysis of a randomized trial of the French Federation of Cancer Centers (F.F.C.C.).
Lacour J, Laplanche A, Delozier T, Berlie J, Mourali N, Julien JP, De Gislain C, Namer M, Petit JC, Denis V, et al. Lacour J, et al. Among authors: de gislain c. Breast Cancer Res Treat. 1991 Sep;19(1):15-21. doi: 10.1007/BF01975200. Breast Cancer Res Treat. 1991. PMID: 1756263 Clinical Trial.
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.
Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Chirgwin J, et al. Breast Cancer Res Treat. 2012 Jan;131(1):295-306. doi: 10.1007/s10549-011-1741-6. Epub 2011 Sep 4. Breast Cancer Res Treat. 2012. PMID: 21892704 Free PMC article. Clinical Trial.
[Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma].
Mornex F, Thomas L, Mohr P, Hauschild A, Delaunay MM, Lesimple T, Tilgen W, Nguyen BB, Guillot B, Ulrich J, Bourdin S, Mousseau M, Cupissol D, Bonneterre J, de Gislain C, Bensadoun JR, Clavel M. Mornex F, et al. Among authors: de gislain c. Cancer Radiother. 2003 Feb;7(1):1-8. doi: 10.1016/s1278-3218(02)00284-6. Cancer Radiother. 2003. PMID: 12648711 Clinical Trial. French.
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
BIG 1-98 Collaborative Group; Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS. BIG 1-98 Collaborative Group, et al. N Engl J Med. 2009 Aug 20;361(8):766-76. doi: 10.1056/NEJMoa0810818. N Engl J Med. 2009. PMID: 19692688 Free PMC article. Clinical Trial.
[Randomized placebo trial of myeloprotection with goralatide in patients with squamous cell carcinoma of the upper respiratory and digestive tracts or esophagus, treated with a carboplatin-fluorouracil combination].
Cappelaere P, Hecquet B, Rolland F, Meeus L, Domenge C, Krakowski I, De Gislain C, Chauvergne J, Dufour-Esquerré F, Carde P. Cappelaere P, et al. Among authors: de gislain c. Bull Cancer. 1995 Sep;82(9):732-7. Bull Cancer. 1995. PMID: 8535033 Clinical Trial. French.
23 results